Eberconazole

Source: Wikipedia, the free encyclopedia.
Eberconazole
Clinical data
Trade namesEbernet
Legal status
Legal status
  • US: Not FDA approved
Identifiers
  • 1-(1,3-Dichloro-6,11-dihydro-5H-dibenzo[1,2-a:1',4'-e] [7]annulen-11-yl)imidazole
JSmol)
  • C1CC2=CC(=CC(=C2C(C3=CC=CC=C31)N4C=CN=C4)Cl)Cl
  • InChI=1S/C18H14Cl2N2/c19-14-9-13-6-5-12-3-1-2-4-15(12)18(17(13)16(20)10-14)22-8-7-21-11-22/h1-4,7-11,18H,5-6H2
  • Key:MPTJIDOGFUQSQH-UHFFFAOYSA-N

Eberconazole is an

antifungal drug. As a 1% topical cream, it is an effective treatment for dermatophytosis, candidiasis, and pityriasis.[1][2][3]

It was approved for use in Spain in 2015 and is sold under the trade name Ebernet.[4] It is also approved for use in Panama, Guatemala, Costa Rica, Honduras, and the Dominican Republic.[1]

References

  1. ^ a b "Ebernet". NewBridge Pharmaceuticals. Archived from the original on 2016-04-24. Retrieved 2017-01-15.
  2. PMID 11486455
    .
  3. PMID 16700802
    .
  4. ^ "Eberconazole". Drugs.com. Archived from the original on 2021-01-17. Retrieved 2017-01-15.


drug article is a stub. You can help Wikipedia by expanding it.

Retrieved from "https://en.wikipedia.org/w/index.php?title=Eberconazole&oldid=1220613443"